The U.S. Court of Appeals for the Federal Circuit denied Genentech’s request to halt sales of Amgen’s Mvasi biosimilar while it appeals a trial court ruling that let the sales proceed.
The Federal Circuit on Aug. 7 had denied a similar request involving Amgen’s Kanjinti.
Mvasi is a biosimilar of Genentech’s colorectal cancer drug Avastin; Kanjinti is biosimilar of its Herceptin.
Amgen has conceded infringing Genentech patents; the issue before the trial court is their validity.
Genentech had argued the biosimilars should be kept off the market until the validity issues are resolved; Amgen said Genentech waited too long to ...